Rocuronium Injection Syringes Recalled for Sterility Assurance Deficiency
FDA recalls 77,554 rocuronium syringes nationwide due to lack of sterility assurance and inadequate validation data for sterilization processes. The drug was repackaged by Central Admixture Pharmacy Services, Inc.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of an injectable drug with sterility deficiency. Rocuronium is a high-risk injectable medication, and lack of sterility assurance creates potential contamination risk. No illnesses or injuries reported in the source text.
Plain-English summary
Rocuronium 50 mg/5 mL (10 mg/mL) injection syringes manufactured by Central Admixture Pharmacy Services, Inc. are being recalled. The FDA initiated this recall due to the manufacturer's lack of assurance of sterility. Specifically, validation data for decontamination cycles is lacking, which means the sterilization process has not been adequately validated.
Approximately 77,554 syringes are affected by this recall. The syringes were distributed nationwide in the United States. Multiple lot numbers are affected with expiration dates ranging from July 2023 to August 2023.
Healthcare facilities and providers should immediately stop using any rocuronium syringes from the affected lots and contact Central Admixture Pharmacy Services for instructions on returning or disposing of the recalled product. For a complete list of affected lot numbers, consult the FDA's official recall notice.
The recalled product
- Product
- rocuronium50 mg/5 mL (10 mg/mL), Syringes Rx only, this drug was repackaged by CAPS Inc, 2200 South 43rd Avenue, Pheonix, AZ, NDC 72196-6010-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable Drug
- Affected units
- 77,554
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 36-238805
- 36-238806
- 36-238808
- 36-238809
- 36-238810
- 36-238811
- Exp. 7/10/2023
- 36-239229
- 36-239319
- 36-239320
- 36-239321
- 36-239322
- Exp. 7/11/2023
- 36-239453
- 36-239454
- 36-239455
- Exp. 7/12/2023
- 36-239851
- 36-239852
- Exp. 7/13/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 95 recalled by Central Admixture Pharmacy Services, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 95 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services, Inc.
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · sterility failure
See all →- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereTransvenous Pacing Electrode Tray with Bipolar Balloon Pacing Electrode Recalled
FDA (Devices) · 2026-07-22
- SevereArterial Line Kit with Lidocaine HCL Injection Fails Sterility Testing
FDA (Devices) · 2026-07-22
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22